Viva Biotech Holdings (1873.HK)

HKD 1.35

(0.0%)

EBITDA Summary of Viva Biotech Holdings

  • Viva Biotech Holdings's latest annual EBITDA in 2023 was 391.01 Million CNY , up 36.16% from previous year.
  • Viva Biotech Holdings's latest quarterly EBITDA in 2024 Q2 was 215.46 Million CNY , down 0.0% from previous quarter.
  • Viva Biotech Holdings reported an annual EBITDA of -89.03 Million CNY in 2022, up 17.95% from previous year.
  • Viva Biotech Holdings reported an annual EBITDA of 369.93 Million CNY in 2021, up 125.09% from previous year.
  • Viva Biotech Holdings reported a quarterly EBITDA of N/A for 2023 FY, up 36.16% from previous quarter.
  • Viva Biotech Holdings reported a quarterly EBITDA of 228.13 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual EBITDA Chart of Viva Biotech Holdings (2023 - 2016)

Historical Annual EBITDA of Viva Biotech Holdings (2023 - 2016)

Year EBITDA EBITDA Growth
2023 391.01 Million CNY 36.16%
2022 -89.03 Million CNY 17.95%
2021 369.93 Million CNY 125.09%
2020 -223.89 Million CNY 132.18%
2019 70.78 Million CNY 17.7%
2018 60.14 Million CNY 3.22%
2017 58.26 Million CNY 80.9%
2016 32.2 Million CNY 0.0%

Peer EBITDA Comparison of Viva Biotech Holdings

Name EBITDA EBITDA Difference
Uni-Bio Science Group Limited 91.23 Million HKD -328.581%
CK Life Sciences Int'l., (Holdings) Inc. 486.79 Million HKD 19.676%